Tucker Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Tucker Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$5.9K	Buy	+1,442	New	+$7.14K	﹤0.01%	669
2025 Q1	–	Sell	-1,442	Closed	-$9.75K	–	806
2024 Q4	$9.75K	Buy	+1,442	New	+$9.7K	﹤0.01%	771
2024 Q2	–	Sell	-3,091	Closed	-$30.8K	–	1776
2024 Q1	$30.8K	Buy	3,091 +3,000	+3,297%	+$33.4K	0.01%	554
2023 Q4	$897	Hold	91	–	–	﹤0.01%	1267
2023 Q3	$696	Hold	91	–	–	﹤0.01%	1227
2023 Q2	$680	Hold	91	–	–	﹤0.01%	1009
2023 Q1	$607	Buy	+91	New	+$722	﹤0.01%	1036
2022 Q2	–	Sell	-30	Closed	-$215	–	693
2022 Q1	$215	Buy	+30	New	+$319	﹤0.01%	546

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Tucker Asset Management's RXRX Position: Q4 2025 in Review

Tucker Asset Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q4 2025: 1,442 shares worth $5.9K. The stake represents ﹤0.01% of the portfolio and ranks #669 among its holdings. This is a return to the name: Tucker Asset Management previously reported a position in RXRX as recently as Q4 2024.

Tucker Asset Management first reported a position in RXRX in Q1 2022 and has held it in 8 quarters since. The position peaked at $30.8K in Q1 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Tucker Asset Management held 1,442 shares of Recursion Pharmaceuticals worth $5.9K as of Q4 2025.
Recursion Pharmaceuticals was a new Tucker Asset Management position in Q4 2025.
Recursion Pharmaceuticals made up ﹤0.01% of Tucker Asset Management's portfolio in Q4 2025, its #669 holding.
Tucker Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
Tucker Asset Management's Recursion Pharmaceuticals position peaked at $30.8K in Q1 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Tucker Asset Management's 13F filing for Q4 2025, filed 5 Feb 2026.